<DOC>
	<DOCNO>NCT02798367</DOCNO>
	<brief_summary>National clinical trial , phase III/II , combine two stage , randomize , double-blind , control , parallel , study superiority , two hundred fifty-six ( 256 ) participant sex , age equal 55 year randomly allocate one three treatment group . In first stage . The group 01 use Melatonin 3mg plus CBT-I , group 02 use Melatonin 5mg plus CBT-I group 03 use CBT-I plus placebo . Based result interim analysis make decision whether proceed study , , dose select second stage study , good study . The final analysis treatment , melatonin select dose plus CBT-I versus CBT-I alone placebo , include participant stage .</brief_summary>
	<brief_title>Melatonin 3mg 5mg Compared Cognitive Behavioral Therapy Insomnia ( CBT-I ) Treatment Insomnia</brief_title>
	<detailed_description>The treatment insomnia disorder accomplish pharmacological nonpharmacological approach . Behavioral technique Sleep Hygiene Stimuli control use . The Sleep hygiene psychoeducational intervention teach patient prevent external environmental factor generate adverse effect harmful sleep . The stimulus control technique base five instruction encourage patient establish proper sleep-wake rhythm strengthens link way quick sleep well establish . Melatonin hormone participate regulation sleep-wake cycle , produce secrete primarily pineal gland dark period prepares individual sleep . Melatonin involved induction sleep proven therapeutic action insomnia disorder , may also play role circadian timing system mammal serve marker `` biological clock '' .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Fulfill criterion insomnia disorder , accord DSM5 ( Diagnostic Statistical Manual Mental Disorders , 5th Edition ) ; Complaint difficulty fall asleep ; Ability understand consent participation clinical study , express signing Informed Consent Form ( ICF ) . Any finding clinical/physical observation laboratory examination interpret investigator risk inclusion participant clinical study ; Known hypersensitivity drug component use study ; Participant family relationship second degree bond employee employee Sponsor Sites ; Participant use betablockers , psychoactive drug sedative effect , , limited antidepressant , sedative , antiepileptic , hypnotic , antipsychotic , muscle relaxant , antihistamine first generation , among others , last 30 day prior screen visit ; Participants diagnose clinical disease interfere sleep , chronic pain , nocturia , hypothyroidism , hyperthyroidism , severe heart disease , serious neurological psychiatric disorder ; Participants diabetic insulin dependent ; Sleep apnea moderate severe ; Participants work night ; Participant BMI â‰¥ 30 ; Participant score 50 Anxiety Inventory assess degree anxiety ; Participant cognitive impairment , base result obtain MiniMental State Examination ; Participant score 20 Beck Inventory assess depression ; Abuse alcohol illicit drug , accord assessment investigator ; Male participant agree use acceptable method contraception ; Participant participate clinical trial protocol last twelve ( 12 ) month ( CNS Resolution 251 August 7 , 1997 , Part III , subitem J ) , unless investigator considers may direct benefit .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>insomnia</keyword>
	<keyword>cognitive behavioral therapy insomnia</keyword>
	<keyword>melatonin</keyword>
</DOC>